Pre-made Varlilumab benchmark antibody ( Whole mAb, anti-CD27 therapeutic antibody, Anti-T14/S152/Tp55/TNFRSF7/S152. LPFS2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Varlilumab biosimilar, Whole mAb, Anti-CD27 Antibody: Anti-T14/S152/Tp55/TNFRSF7/S152. LPFS2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Varlilumab (INN; development code CDX-1127) is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies. It is an anti-CD27 antibody and helps activate T-cells.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-614-1mg	1mg	3090
GMP-Bios-ab-614-10mg	10mg	Inquiry
GMP-Bios-ab-614-100mg	100mg	Inquiry
GMP-Bios-ab-614-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Varlilumab biosimilar, Whole mAb, Anti-CD27 Antibody: Anti-T14/S152/Tp55/TNFRSF7/S152. LPFS2 therapeutic antibody
INN Name	Varlilumab
Target	CD27
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2014
Year Recommended	2015
Companies	Celldex Therapeutics Inc;Oncothyreon;University of California at San Francisco;University of Virginia
Conditions Approved	na
Conditions Active	Malignant melanoma;Solid tumours;Non-Hodgkin's lymphoma;Renal cell carcinoma;Glioblastoma
Conditions Discontinued	Haematological malignancies;Prostate cancer;Breast cancer;Ovarian cancer;Glioma
Development Tech	na